“It is 2020: Time to act on the much improved prostate cancer screening harm/benefit ratio”
Prof. Monique Roobol is professor Decision Making in Urology and the head of the scientific research office within the Department of Urology at the Erasmus Medical Centre Rotterdam, The Netherlands. She has a master and a PhD degree in epidemiology.
She has completely dedicated the past twenty years to research on early detection of prostate cancer. Next to her significant contribution to the European Randomized study of Screening for Prostate Cancer (ERSPC), she co-developed the Rotterdam Prostate Cancer Risk Calculator, a multi-step risk analysis tool to guide laymen and physicians in decision making at diagnosis, and the PRIAS (Prostate cancer Research International Active Surveillance), a study on active surveillance.
The scientific research office at the Erasmus Medical Centre performs and supports several clinical and population-based screening studies. On average, five PhD students work under Prof. Roobol’s guidance. She is currently the principal investigator (PI) of ERSPC and co-PI of PRIAS and the Movember Global Action Plan-3 (on active surveillance). Since 2018, she has been part of the PIONEER European network for big data in prostate cancer.
Prof. Roobol’s research has been awarded with several prizes, such as the bi-annual Van Stockum Prize for best thesis from the Dutch Urological Association, the EAU Prize for the Best Paper published on Clinical Research (in 2010), the European Urology Platinum Award (2011 and 2018), and the BJUI Best Urological Mobile Application Award (2015).